<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954444</url>
  </required_header>
  <id_info>
    <org_study_id>OXY2018-01</org_study_id>
    <nct_id>NCT03954444</nct_id>
  </id_info>
  <brief_title>A Clinical Endpoint Bioequivalence Study of &quot;Oxymetazoline Hydrochloride Cream&quot;</brief_title>
  <official_title>A Randomized, Double Blind, Parallel Group, Three Arm, Placebo Controlled, Multi-Site Therapeutic Equivalence Study With Clinical End-points Comparing Test Product &quot;Oxymetazoline Hydrochloride Cream, 1%&quot; to Reference Product &quot;RHOFADETM Cream, 1%&quot; in the Treatment of Moderate to Severe Persistent Facial Erythema of Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site
      Therapeutic Equivalence Study with Clinical End-points Comparing Test Product &quot;Oxymetazoline
      hydrochloride Cream, 1%&quot; to Reference Product &quot;RHOFADE™ Cream, 1%&quot; in the Treatment of
      Moderate to Severe Persistent Facial Erythema of Rosacea
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 7, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The therapeutic equivalence between test and reference for baseline-adjusted AUEC(ss)</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The therapeutic equivalence between test and reference for baseline-adjusted Emax(ss)</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The therapeutic equivalence between test and reference for baseline-adjusted AUEC</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The therapeutic equivalence between test and reference for baseline-adjusted Emax</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1103</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Oxymetazoline hydrochloride Cream, 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxymetazoline hydrochloride cream, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RHOFADE Cream, 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RHOFADE Cream, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymetazoline Hydrochloride</intervention_name>
    <description>Test Comparator</description>
    <arm_group_label>Oxymetazoline hydrochloride Cream, 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rhofade Cream, 1%</intervention_name>
    <description>Reference Comparator</description>
    <arm_group_label>RHOFADE Cream, 1%</arm_group_label>
    <other_name>Oxymetazoline hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <other_name>Oxymetazoline hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Study subjects must have provided IRB approved written informed consent using the
             latest version of the IRB informed consent form, (or assent in applicable
             states/countries). In addition, study subjects must sign a HIPAA authorization, if
             applicable.

          -  (2) Healthy male or non-pregnant females, ≥18 years-of-age with a clinical diagnosis
             of rosacea with persistent (non-transient) facial erythema.

          -  (3) Ability to follow study instructions and complete subject diary without
             assistance.

          -  (4) Females of child bearing potential must not be pregnant or lactating at screening
             visit and at baseline visit, as documented by a negative urine pregnancy test.

          -  (5) Female subjects of childbearing potential must be willing to use an acceptable
             form of birth control from the day of the first dose administration to 30 days after
             the last administration of Investigational Product (IP). A sterile sexual partner is
             NOT considered an adequate form of birth control.

          -  (6) Moderate to severe persistent facial erythema associated with rosacea, defined as
             a grade of ≥3 on the CEA scale as assessed by the Investigator at Screening and on
             Baseline (Day 1) visit prior to study drug application.

          -  (7) Moderate to severe persistent facial erythema associated with rosacea, defined as
             a grade of ≥3 on the SSA scale as assessed by the subject at Screening and on Baseline
             (Day 1) visit prior to study drug application.

          -  (8) Stable erythema (for at least 3 months prior to screening) associated with
             rosacea, with minimal variation from day to day and within each day, in the opinion of
             the subject.

          -  (9) Willingness to complete the required visits including short stay for at least 12
             hours at the investigational site for 2 separate visits.

          -  (10) Subjects who use make-up, facial moisturizers, creams, lotions, cleansers and/or
             sunscreens must have used the same product brands/types for a minimum period of 4
             weeks prior to Baseline, must agree not to change brand/type or frequency of use
             throughout the study and must agree not to use make-up, facial moisturizers, creams,
             lotions and/or sunscreens on the scheduled clinic visit day before the visit.

          -  (11) Subject must be willing to avoid the use of abrasive cleansers or washes (e.g.,
             exfoliating facial scrubs), adhesive cleansing strips (e.g., Bioré® Pore Strips) and
             wax epilation on the face, during the entire duration of their study participation.

          -  (12) Subject's willingness to minimize external factors that might trigger rosacea
             flare-ups (e.g., spicy foods, thermally hot foods and drinks, hot environments,
             prolonged sun exposure, strong winds, alcoholic beverages).

          -  (13) Subject must be in good health and free from any systemic or dermatological
             disorder (other than rosacea) that, in the opinion of the Investigator, will interfere
             with the study evaluations or increase the risk of AEs.

          -  (14) Any skin type or race, providing the skin pigmentation will allow discernment of
             erythema.

        Exclusion Criteria:

          -  (1) Any of the following conditions: severe or unstable or uncontrolled cardiovascular
             disease, clinically unstable hypertension, orthostatic hypotension, and uncontrolled
             hypertension or hypotension, cerebral or coronary insufficiency, Raynaud's Syndrome,
             thromboangiitis obliterans, scleroderma, Sjögren's syndrome, renal or hepatic
             impairment.

          -  (2) Subjects with narrow angle glaucoma.

          -  (3) Females who are pregnant, breast feeding, or planning a pregnancy during the
             study.

          -  (4) Females of childbearing potential who do not agree to utilize an adequate form of
             contraception during their participation in the study.

          -  (5) Clinical signs of particular forms of rosacea (rosacea conglobata, rosacea
             fulminans, isolated rhinophyma, isolated pustulosis of the chin) on the face or other
             concomitant facial dermatoses that are similar to rosacea such as peri-oral
             dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute
             lupus erythematosus, or actinic telangiectasia that may interfere with the study
             evaluations, in the opinion of the Investigator.

          -  (6) Presence of ≥3 facial inflammatory lesions of rosacea at screening and baseline.

          -  (7) Presence of any skin condition on the face that would interfere with the diagnosis
             or assessment of rosacea, as determined by the Investigator.

          -  (8) Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would
             interfere with the study treatments or study assessments.

          -  (9) History of drug or alcohol abuse within 12 months prior to the Screening visit.

          -  (10 Known hypersensitivity or allergies to any component of the study treatment.

          -  (11) Use within 12 hours prior to baseline of any topical products including, but not
             limited to, lotions, creams, ointments, and cosmetics applied to the face (facial
             cleanser is acceptable).

          -  (12) Use 1 week prior to baseline of niacin ≥500 mg/day.

          -  (13) Use within 2 weeks prior to baseline of products containing topical
             corticosteroids, topical retinoids, topical antibiotics, topical anti-inflammatory,
             topical treatment for rosacea, or topical treatment for acne.

          -  (14) Use within 4 weeks prior to baseline of topical immunomodulators, systemic
             antibiotics, systemic corticosteroids, systemic anti-inflammatory agents, systemic
             treatment for rosacea, or systemic treatment for acne (other than oral retinoids,
             which require a 6-month washout).

          -  (15) Undergone 4 weeks prior to baseline any dermatologic or surgical procedure on the
             face.

          -  (16) Use within 3 months prior to baseline of any systemic immunomodulators known to
             have an effect on rosacea.

          -  (17) Use within 6 months prior to baseline of any oral retinoids (e.g., isotretinoin)
             or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins
             are allowed).

          -  (18) Undergone 6 months prior to baseline any laser, light-source (e.g. intense pulsed
             light, photodynamic therapy) or other energy-based therapy to the face.

          -  (19) Exposed to excessive UV radiation within 1 week before Screening visit and/or
             subject is unwilling to refrain from excessive exposure to UV radiation during the
             course of the study.

          -  (20) Current use of monoamine oxidase (MAO) inhibitors, barbiturates, opiates,
             sedatives, systemic anesthetics, alpha-agonists, cardiac glycosides, beta blockers,
             other antihypertensive agents, or oxymetazoline (e.g., eye drops, nasal sprays).

          -  (21) Subject has participated in a clinical trial within 30 days or in a biologics
             study within 6 months preceding admission of this study.

          -  (22) Previous participation in this study.

          -  (23) Inability to communicate well (i.e., language problem, poor mental development,
             psychiatric illness or poor cerebral function), that may impair the ability to provide
             written informed consent.

          -  (24) Subject has any evidence of organ dysfunction, chronic infectious disease, system
             disorder or has a condition or is in a situation that, in the Investigator's opinion,
             that may put the subject at significant risk, may confound the study results, or may
             significantly interferes with the subject's participation in the study.

          -  (25) Employees or family members of the research center or Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

